AU2020228036B2 - Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia - Google Patents

Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia

Info

Publication number
AU2020228036B2
AU2020228036B2 AU2020228036A AU2020228036A AU2020228036B2 AU 2020228036 B2 AU2020228036 B2 AU 2020228036B2 AU 2020228036 A AU2020228036 A AU 2020228036A AU 2020228036 A AU2020228036 A AU 2020228036A AU 2020228036 B2 AU2020228036 B2 AU 2020228036B2
Authority
AU
Australia
Prior art keywords
triterpenoid
antifungals
pneumonia
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020228036A
Other languages
English (en)
Other versions
AU2020228036A1 (en
Inventor
David A. ANGULO GONZALEZ
Stephen Andrew BARAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
SCYNEXIS Inc
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCYNEXIS Inc, Scynexis Inc filed Critical SCYNEXIS Inc
Publication of AU2020228036A1 publication Critical patent/AU2020228036A1/en
Application granted granted Critical
Publication of AU2020228036B2 publication Critical patent/AU2020228036B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2020228036A 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia Active AU2020228036B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27
US62/811,456 2019-02-27
PCT/US2020/019724 WO2020176527A1 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Publications (2)

Publication Number Publication Date
AU2020228036A1 AU2020228036A1 (en) 2021-09-23
AU2020228036B2 true AU2020228036B2 (en) 2025-08-07

Family

ID=70005768

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020228036A Active AU2020228036B2 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia

Country Status (15)

Country Link
US (1) US12594266B2 (https=)
EP (1) EP3930716B1 (https=)
JP (1) JP7581219B2 (https=)
KR (1) KR20210133241A (https=)
CN (1) CN113631165A (https=)
AU (1) AU2020228036B2 (https=)
BR (1) BR112021016876A2 (https=)
CA (1) CA3131298A1 (https=)
EA (1) EA202192344A1 (https=)
ES (1) ES3055272T3 (https=)
IL (1) IL285839A (https=)
MA (1) MA55081A (https=)
MX (2) MX2021010311A (https=)
TW (1) TWI910099B (https=)
WO (1) WO2020176527A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis", 2018 *
BARAT S., et al., "PP2.091 - SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.", ISHAM 2018. *
MELANIE CUSHION, ASHBAUGH ALAN, BORROTO-ESODA KATYNA, BARAT STEPHEN, GONZALEZ DAVID ANGULO: "P1226 SCY-078 demonstrates antifungal activity against pneumocystis in a prophylactic murine model of pneumocystis pneumonia", 28TH ECCMID, 24 April 2018 (2018-04-24) - 24 April 2018 (2018-04-24), XP055697357 *

Also Published As

Publication number Publication date
MX2021010311A (es) 2022-01-04
JP2022523212A (ja) 2022-04-21
KR20210133241A (ko) 2021-11-05
WO2020176527A1 (en) 2020-09-03
US12594266B2 (en) 2026-04-07
AU2020228036A1 (en) 2021-09-23
TWI910099B (zh) 2026-01-01
MA55081A (fr) 2022-01-05
JP7581219B2 (ja) 2024-11-12
EP3930716B1 (en) 2025-09-10
IL285839A (en) 2021-10-31
EP3930716A1 (en) 2022-01-05
CN113631165A (zh) 2021-11-09
BR112021016876A2 (pt) 2021-11-03
MX2025004197A (es) 2025-09-02
ES3055272T3 (en) 2026-02-10
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
US20230149376A1 (en) 2023-05-18
EA202192344A1 (ru) 2021-11-15

Similar Documents

Publication Publication Date Title
EP3980400A4 (en) PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS
HK1254843A1 (en) Compositions comprising bacterial strains
CA3295543A1 (en) Cargo sensors, cargo-sensing units, cargo-sensing systems, and methods of using the same
HK1254843B (zh) 包含细菌菌株的组合物
EP4218785A3 (en) Mitochondria-targeting peptides
EP4049159A4 (en) PREVENTING RANSOMWARE
EP4327876A3 (en) Immunogenic compositions
WO2017011340A3 (en) Proteins and immunizing compositions containing klebsiella proteins and methods of use
GB201815025D0 (en) Insect-pathogenic fungus, spores, composition and use of same
GB201911925D0 (en) Formulations for prevention or reduction of c. difficile infections
AU2020228036B2 (en) Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
EP4056235A4 (en) OIL-IN-WATER COMPOSITION
EP3165229B8 (en) Composition for the prevention or treatment of polycystic ovary syndrome and its related symptoms
EP3876906A4 (en) MEANS AND METHODS TO PREVENT OR REVERSE AGING
EP3908187A4 (en) IMAGING SYSTEMS AND METHODS OF OPERATING THEREOF
ZA201808182B (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
LT3630092T (lt) Kompozicija, kurios pagrindą sudaro vitaminas e arba jo esteris, skirta bakterijų ir grybelių bioplėvelėms gydyti
EP4025258A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
EP3804710A4 (en) MEANS OF PREVENTING OR IMPROVING NYCTURIA
EP3511408A4 (en) COMPOSITION FOR THE TREATMENT OR PREVENTION OF VIRAL INFECTIONS
HK40078446A (en) Dynamic monosaccharide control processes
MX2021013776A (es) Composiciones que comprenden cepas bacterianas.
HK40086190A (en) Treating & preventing microbial infections
HK40086190B (en) Treating & preventing microbial infections
HK40036948A (en) Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)